| 朱跃蔡丽毕雅莉吴琼琼王瑞娜.放射性粒子碘125 插置组织间治疗晚期肿瘤的临床疗效[J].,2014,14(15):2929-2932 |
| 放射性粒子碘125 插置组织间治疗晚期肿瘤的临床疗效 |
| Effects of Radioactive 125-Iodine Seed Implantation for the Treatment ofAdvanced Tumor |
| |
| DOI： |
| 中文关键词: 碘125 晚期肿瘤 肺癌 |
| 英文关键词: 125I Advanced tumor Lung cancer |
| 基金项目: |
|
| 摘要点击次数: 605 |
| 全文下载次数: 805 |
| 中文摘要: |
| 摘要目的：探讨放射性粒子碘125 插置组织间治疗晚期肿瘤的疗效。方法：选择2008 年7 月至2011 年4 月经我院收治的晚期
肿瘤患者95 例，全部患者均经放射性粒子碘125 插置组织间治疗，观察患者疗效、不良反应、免疫指标及肿瘤标志物水平，并随
访6-24月观察患者生存率。结果：95 例患者临床有效率为83.15%，其中CR 23 例（24.21%），PR 56 例（58.94%），PD 9例（9.47%），
SD 7例（7.37%）。在碘125 插置过程中出现7 例气胸，术后出现2 例咳血、1 例排便困难和3 例出现发热并伴穿刺处疼痛。全部患
者治疗前后IgG、IgA和IgM水平无显著性变化（P>0.05），而治疗后4 周各病种晚期肿瘤患者相应肿瘤标志物水平显著低于治疗
前，差异有统计学意义（P<0.05）。53 例肺癌患者中，半数生存期为20 个月，术后1、2 年生存率分别为86.79%和41.51%；而同期行
姑息手术且未接受放射性粒子碘125 插置组织间治疗的40 例肺癌患者，半数生存期仅为12 个月，术后1、2 年生存率分别为
57.50%和22.50%，两组比较，差异有统计学意义（P<0.05）。结论：放射性粒子碘125 插置组织间治疗晚期肿瘤具有适应症广、安全
性高、临床效果好和不良反应少等优点，还可提高晚期肿瘤患者的生存期。 |
| 英文摘要: |
| ABSTRACT Objective:To discuss the effects of radioactive 125-Iodine seed implantation for advanced tumor. Methods:A total
of 95 advanced tumor patients were retrospectively analyzed from 2008 July to 2011 April. These patients were treated by radioactive
125-Iodine seed implantation. Curative effect, side-effect, immune globulin and tumor marker levels were observed.And survival of the
patients were followed up for 6 to 24 months observation. Results:The total effect rate was 83.15%, including CR(23 cases, 24.21%), PR
(56 cases, 58.94%), PD (9 cases, 9.47%), SD (7 cases, 7.37%). Of the 95 patients, there were 7 cases of pneumothorax, 2 cases of
hemoptysis, 1 case of defecation difficulty, and 3 cases with fever and with piercing pain. Comparison before and after treatment, there
was no significant change of IgG, IgA and IgMlevel (P>0.05); but 4 weeks after treatment, the tumor marker levels were all significantly
lowered (P<0.05). The median survival time, postoperative 1, 2 year survival rates (20 months, 86.79%and 41.51% respectively) of lung
cancer observation group were significantly higher than lung cancer control group (12 months, 57.50% and 22.50% respectively), with
significant difference (P<0.05). Conclusion:Radioactive 125-Iodine seed implantation has wide indications, high security, good clinical
effect and less adverse reaction, and also can improve the survival period of patients with advanced tumors. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
